Deksloksiglumid

Deksloksiglumid
IUPAC ime
	(4R)-4-[(3,4-dichlorobenzoyl)amino]-5-(3-methoxypropylpentylamino)-5-oxopentanoic acid
Identifikatori
CAS broj	119817-90-2
ATC kod	none
PubChem	CID 65937
IUPHAR/BPS	889
Hemijski podaci
Formula	C21H30Cl2N2O5
Molarna masa	461.379 g/mol
	SMILES CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl; ;

Deksloksiglumid je lek koji deluje kao holecistokininski antagonist, koji je selektivan za CCK_A tip receptora. On inhibira gastrointestinalnu motilnost i redukuje želudačnu sekreciju. Mada stariji selektivni CCK_A antagonisti poput lorglumida i devazepida nisu dospeli do kliničkih upotrebe, deksloksiglumid se istražuje kao potencijalni lek za niz gastrointestinalnih problema, među kojima je upalna bolest creva,^[1] dispepsija,^[2] konstipacija^[3] i pankreatitis.^[4]^[5]

Reference

^ Cremonini, F.; Camilleri, M.; McKinzie, S.; Carlson, P.; Camilleri, C. E.; Burton, D.; Thomforde, G.; Urrutia, R.; Zinsmeister, A. R. (2005). „Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: A pharmacodynamic and pharmacogenomic study”. The American Journal of Gastroenterology. 15743365 (3): 652—663. PMID 15743365. S2CID 34227592. doi:10.1111/j.1572-0241.2005.41081.x.
^ Galligan, J. J.; Vanner, S. (2005). „Basic and clinical pharmacology of new motility promoting agents”. Neurogastroenterology and Motility. 16185302 (5): 643—653. PMID 16185302. S2CID 7298061. doi:10.1111/j.1365-2982.2005.00675.x.
^ Roberts, D. J.; Banh, H. L.; Hall, R. I. (2006). „Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients”. Current Opinion in Critical Care. 16810038 (4): 295—302. PMID 16810038. S2CID 32307333. doi:10.1097/01.ccx.0000235205.54579.5d.
^ Maselli, M. A.; Mennuni, L. (2003). „CCK1 receptor antagonist, dexloxiglumide: Effects on human isolated gallbladder. Potential clinical applications”. Minerva Gastroenterologica e Dietologica. 16484960 (3): 211—216. PMID 16484960.
^ Barrett, T. D.; Yan, W.; Freedman, J. M.; Lagaud, G. J.; Breitenbucher, J. G.; Shankley, N. P. (2008). „Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction”. British Journal of Pharmacology. 18297100 (8): 1650—1658. PMC 2438255 . PMID 18297100. doi:10.1038/bjp.2008.44.

Spoljašnje veze

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Cremonini, F.; Camilleri, M.; McKinzie, S.; Carlson, P.; Camilleri, C. E.; Burton, D.; Thomforde, G.; Urrutia, R.; Zinsmeister, A. R. (2005). „Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: A pharmacodynamic and pharmacogenomic study”. The American Journal of Gastroenterology. 15743365 (3): 652—663. PMID 15743365. S2CID 34227592. doi:10.1111/j.1572-0241.2005.41081.x.

[2] Galligan, J. J.; Vanner, S. (2005). „Basic and clinical pharmacology of new motility promoting agents”. Neurogastroenterology and Motility. 16185302 (5): 643—653. PMID 16185302. S2CID 7298061. doi:10.1111/j.1365-2982.2005.00675.x.

[3] Roberts, D. J.; Banh, H. L.; Hall, R. I. (2006). „Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients”. Current Opinion in Critical Care. 16810038 (4): 295—302. PMID 16810038. S2CID 32307333. doi:10.1097/01.ccx.0000235205.54579.5d.

[4] Maselli, M. A.; Mennuni, L. (2003). „CCK1 receptor antagonist, dexloxiglumide: Effects on human isolated gallbladder. Potential clinical applications”. Minerva Gastroenterologica e Dietologica. 16484960 (3): 211—216. PMID 16484960.

[5] Barrett, T. D.; Yan, W.; Freedman, J. M.; Lagaud, G. J.; Breitenbucher, J. G.; Shankley, N. P. (2008). „Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction”. British Journal of Pharmacology. 18297100 (8): 1650—1658. PMC 2438255 . PMID 18297100. doi:10.1038/bjp.2008.44.

[1]

[2]

[3]

[4]

[5]